Ansa Biotechnologies

Ansa is a biotech company that is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.

Ansa is on a mission to streamline the writing of DNA to power the next era of DNA-enabled industries. 

Ansa Biotechnologies was founded in 2018 by Daniel Lin-Arlow and Sebastian Palluk. The company is headquartered in Berkeley, California.

 

Ansa’s novel enzymatic synthesis technology harnesses the power of nature’s machinery to synthesize DNA in an entirely new way that is substantially faster and more accurate than the chemical method.

 

Ansa’s enzyme-based approach will dramatically accelerate innovation across almost every industry enabled by synthetic DNA-- from biologic therapeutics such as antibodies, gene therapies, and cell therapies, to the biomanufacturing of chemicals, materials, foods, and biofuels, and even to futuristic applications such as DNA-based data storage.

 

Ansa is backed by Northpond Ventures, Horizons Ventures, Mubadala Capital, RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Humboldt Fund, Fifty Years, and others. The company raised $68M in Series A round on Apr 11, 2022. This brings Ansa's total funding to $77.2M to date.

 

 

  • Year founded: 2018
  • Funding Info: $77.2M over 3 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Berkeley
  • State: California
  • Country: United States
Related businesses